ClinicalTrials.gg
RecruitingNCT07310420Updated Nov 12, 2026

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

A Phase 1 interventional study of ZOLADEX in Advanced Breast Cancer and Early Breast Cancer, sponsored by TerSera Therapeutics LLC. Recruiting at 28 sites in United States. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by TerSera Therapeutics LLC · Phase 1, Interventional, and Treatment

Updated Nov 12, 2026Start date moved7 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
176
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing goserelin in Breast Neoplasms — 7 open to participants now, 9 under way, none of them phase 3. Goserelin · Breast Neoplasms.

Planned enrollment
18th of 41
176 · median 147
Started
2026
with 2 others
Phase 1
2 of 43
1 open now
Registered
42nd of 43
by date

Among the 43 studies testing goserelin in Breast Neoplasms, this one is the 18th largest by planned enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2026, is one of 2 in phase 1, and was the 42nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 43 studies testing goserelin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About goserelin

Goserelin: first FDA approval 1989 (ZOLADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing goserelin in Breast Neoplasms, or all of them as a file.
02

Study summary

The primary objective of this trial is to evaluate ovarian suppression following treatment with ZOLADEX 10.8 mg by luteinizing hormone (LH) within each cohort.

Read the detailed description

The purpose of this study is to assess the degree and consistency of ovarian suppression achieved following administration of ZOLADEX 10.8 mg. Ovarian suppression will be evaluated by measuring LH levels over the treatment period.

03

Conditions studied

  • Advanced Breast Cancer
  • Early Breast Cancer

Browse trials for

Keywords

  • Ovarian Suppression
  • ZOLADEX
  • HR+
  • Breast Cancer
  • Goserelin Implant
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age and gender: Female participants aged 18 to 55 years, inclusive.
  2. Hormone receptor positive (HR+): Either estrogen receptor positive (ER+) or progesterone receptor positive (PR+) breast cancer, defined as 1% to 100% of tumor nuclei are positive for ER or PR via immunohistochemistry.
  3. Participants must be of premenopausal status.
  4. Recent radiotherapy:

    1. Prior radiotherapy is allowed.
    2. All radiotherapy-related toxicities (except alopecia) must have recovered to (CTCAE) v6.0 Grade ≤1 before trial enrollment.
  5. Concurrent medications:

    1. Cyclin-dependent kinase 4 (CDK4/6) inhibitors are permitted.
    2. PIK3CA/AKT inhibitors are permitted.
    3. Concomitant use of bisphosphonates is permitted.
    4. Concomitant use of endocrine therapy (eg, aromatase inhibitor, fulvestrant, or other FDA-approved selective estrogen receptor degrader [SERDs]) is permitted.
    5. Concurrent standard-of-care human epidermal growth factor receptor 2 ()- targeted therapy (including but not limited to trastuzumab, pertuzumab, trastuzumab deruxtecan, or T-DM1) is permitted.
  6. : Able to understand and willing to provide informed consent and able to comply with the trial procedures and restrictions.
  7. Abstinence and : Female participants may be enrolled if they are:

    1. Practicing true abstinence for at least 28 days prior to product (IP) administration until 12 weeks after the last IP administration and having a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day -1, OR
    2. Using 2 forms of highly effective nonhormonal contraception, including 1 physical barrier (condom or diaphragm) plus another nonhormonal method (eg, intrauterine device, spermicidals) from Screening or at least 2 weeks prior to IP administration (whichever is earlier) until 12 weeks after the last IP administration and having a negative serum pregnancy test at Screening and a negative urine pregnancy test at Day -1.
  8. Performance status: (ECOG) performance status of 0 to 2.

    Inclusion Criteria specific to the advanced breast cancer cohort:

  9. Advanced breast cancer diagnosis: Histological confirmation of breast cancer with evidence of locally advanced or disease, which is not amenable to surgical resection or radiation therapy with curative intent per investigator's assessment.
  10. Chemotherapy History:

    1. A participant may have received chemotherapy provided the criteria for premenopausal status, as defined in Inclusion Criterion #3, are met at trial screening.
    2. All chemotherapy-related toxicities must have recovered to CTCAE v6.0 ≤Grade 1 before trial participation, except for alopecia, peripheral neuropathy, or paresthesia (≤Grade 2).
  11. Prior treatment:

    1. Participants may have received prior radiotherapy.
    2. Participants may have received or be receiving a cyclin-dependent kinase (CDK) 4/6 inhibitor, a PIK3CA-AKT inhibitor, or bisphosphonates.
    3. Gonadotropin-releasing hormone (GnRH) treatment-naïve participants will have no history of GnRH agonist or other endocrine therapy in the advanced/metastatic setting.
    4. GnRH treatment-exposed participants may have received a GnRH agonist or other endocrine therapy in the advanced/metastatic setting, provided they had established premenopausal status (Inclusion Criterion #3) prior to initiating GnRH agonist therapy, within 6 months prior to trial enrollment.
    5. Participants may have received HER2-targeted therapy (including but not limited to trastuzumab, pertuzumab, trastuzumab deruxtecan, or T-DM1).

    Inclusion Criteria specific to the early-stage breast cancer cohort:

  12. Early-stage breast cancer diagnosis:

    1. confirmed unilateral or bilateral invasive adenocarcinoma of the breast.
    2. Pathologically staged as Stage I, II, or III (specifically T1-T4, N0-N3, M0) at the time of definitive surgery, according to the current American Joint Committee on Cancer (AJCC) Staging Manual.
  13. Chemotherapy history:

    1. A participant may have received or neoadjuvant chemotherapy provided the criteria for premenopausal status, as defined in Inclusion Criterion #3, are met at trial Screening.
    2. All chemotherapy-related toxicities must have recovered to CTCAE v6.0 ≤Grade 1 before trial participation except for alopecia, peripheral neuropathy, or paresthesia (≤Grade 2).
  14. Prior treatment:

    1. Participants may have received prior radiotherapy.
    2. Participants may have received or be receiving a CDK 4/6 inhibitor, a PIK3CA-AKT inhibitor, or bisphosphonates.
    3. GnRH treatment-naïve participants will have no history of GnRH agonist or other endocrine therapy.
    4. GnRH treatment-exposed participants may have received a GnRH agonist or other endocrine therapy provided they had established premenopausal status (Inclusion Criterion #6) prior to initiating GnRH agonist therapy, within 6 months prior to trial enrollment.
    5. Participants may have received HER2-targeted therapy (including but not limited to trastuzumab, pertuzumab, trastuzumab deruxtecan, or T-DM1).

Exclusion criteria

Exclusion Criteria:

  1. : Naturally or surgically postmenopausal (regardless of age).
  2. (BMI): \<18 kg/m\^2 or >35.0 kg/m\^2.
  3. Prior surgical or radiation procedures: History of bilateral oophorectomy or prior radiotherapy to the ovaries.
  4. Selective estrogen receptor modulator (SERM) use during trial: Participants may not receive tamoxifen or other SERMs during the trial and must discontinue any SERMs prior to enrollment, other endocrine therapies (eg, aromatase inhibitor, fulvestrant, or other FDA-approved SERDs) are allowed.
  5. : Known hypersensitivity, idiosyncratic, or allergic reactions to goserelin, GnRH, GnRH agonists/analogs, or any trial drug components.
  6. Expected survival: Estimated \<6 months from the start of trial therapy, based on the principal investigator's (PI) clinical judgment.
  7. Performance status: performance status ≥3.
  8. Life-threatening disease or : Presence of life-threatening metastatic visceral disease, defined as extensive hepatic involvement, symptomatic pulmonary lymphangitic spread, symptomatic pleural disease, or any symptomatic brain/ (proven or suspected). Participants with asymptomatic or stable/treated are eligible to enroll if neurologically stable and are receiving a stable or decreasing dose at the time of enrollment. Participants with discrete pulmonary parenchymal metastases are eligible if respiratory function is not compromised.
  9. Hepatic function:

    1. (ALT) or aspartate aminotransferase (AST) ≥2× (ULN) if no liver metastases, or >5×ULN with liver metastases.
    2. Total ≥1.5×ULN (≥2.5×ULN for Gilbert's syndrome).
  10. Renal function: (CrCl) ≤30 mL/min as calculated by the Cockcroft-Gault formula.
  11. Hematologic parameters:

    1. (Hgb) \<8.0 g/dL.
    2. White blood cell (WBC) count \<3000/mm\^3.
    3. \<100,000/mm\^3.
    4. Eligibility for participants taking CDK4/6 inhibitors should be based on D-1 labs.
    5. An (ANC) \<1500/mm3 on D-1 is exclusionary.
  12. Other : Active malignancy within the past 3 years, except for adequately treated basal or squamous cell skin cancer or in situ cervical carcinoma.
  13. Concurrent medical conditions: Presence of any severe, uncontrolled, or serious illness, medical condition (including psychiatric/addictive disorders), or clinical finding that could compromise trial adherence, as assessed by the investigator.
  14. drug exposure: Exposure to any investigational drug or device within 30 days prior to trial enrollment.
  15. Pregnancy: Participant has with a positive serum pregnancy test or positive urine pregnancy test at Screening or Day 1.
  16. Breastfeeding: Participant is currently breastfeeding.
  17. use: Sexually active with a male partner and not willing to use nonhormonal contraceptive methods throughout the trial. Exceptions: male partner is vasectomized (provided he is her sole sexual partner, and he has received medical assessment of the surgical success), participant has had bilateral salpingectomy or tubal occlusion hysterectomy.
  18. Cardiac conditions:

    1. interval (QTc) using Fridericia's correction (QTcF) >450 ms at Screening.
    2. Uncontrolled or symptomatic heart disease, including:

    i. (NYHA) Class III or IV heart failure.

    ii. Myocardial infarction within the past 6 months.

    iii. Unstable angina or significant arrhythmias requiring intervention.

    c. Documented congenital QT syndrome.

  19. abnormal medical history or abnormal findings on physical examination, vital signs, echocardiogram (), or laboratory tests at Screening that the investigator judges as likely to interfere with the objectives of the trial or the safety of the participant.
  20. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
  21. History of alcohol abuse or drug addiction (including soft drugs like cannabis products) within the last 1 year prior to IP administration.
  22. Major surgery within 30 days prior to IP dosing or a major surgical procedure planned during the trial.
  23. Any other condition that precludes adequate understanding, cooperation, and compliance with trial procedures or any condition that could pose a risk to the participant's safety, as per the investigator's judgment.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    ZOLADEX 10.8 mg

    Participants will receive 10.8 mg ZOLADEX on Day 1 and Day 85.

    Drug: ZOLADEX

Interventions

  • Participants will receive ZOLADEX as a subcutaneous (SC) injection on Day 1 (Week 1), and Day 85 (Week 12) for a total of 2 treatments.

    Also known as: Goserelin implant

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with LH Values Below a Specified Threshold at Week 6 Within Each Cohort

    Time frame: Week 6

Secondary outcomes

  1. Percentage of Participants with LH Values below a Specified Threshold at Weeks 12, 18, and 24 Within Each Cohort

    Time frame: Weeks 12, 18, and 24

  2. Percentage of Participants with Estradiol (E2) Suppression at Weeks 6, 12, 18, and 24 Within Each Cohort

    Time frame: Weeks 6, 12, 18, and 24

  3. Percentage of Participants with Absence of Menses at Weeks 6, 12, 18, and 24 Within Each Cohort

    Time frame: Weeks 6, 12, 18, and 24

07

Study locations

28 of 28 sites recruiting
  • Genesis Cancer and Blood Institute
    Hot Springs, Arkansas 71913, United States
    Recruiting
    • Stephen Divers, MD · Contact
  • MedStar Heart & Vascular Institute (MHVI) - MedStar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
    • Ami Chitalia, MD · Contact
  • Regis Clinical Research
    Miami, Florida 33126, United States
    Recruiting
    • Marreo Rodriguez, MD · Contact
  • Cancer Centers of Florida
    Ocoee, Florida 34761, United States
    Recruiting
    • Gopal Kunta, MD · Contact
  • University Cancer & Blood Center, LLC
    Athens, Georgia 30607, United States
    Recruiting
    • Addie Hill, MD · Contact
  • Summit Cancer Care
    Savannah, Georgia 31405, United States
    Recruiting
    • Mark Taylor, MD · Contact
  • University of Illinois at Chicago
    Chicago, Illinois 60612, United States
    Recruiting
    • Vijayakrishna Gadi, MD · Contact
  • NorthShore University Health System - Evanston Hospital
    Evanston, Illinois 60201, United States
    Recruiting
    • Poornima Saha, MD · Contact
  • Duly Health and Care
    Lisle, Illinois 60532, United States
    Recruiting
    • Daniel Frank, MD · Contact
  • Orchard Healthcare Research
    Skokie, Illinois 60077, United States
    Recruiting
    • Ira Oliff, MD · Contact
  • Springfield Clinic - The Cancer Center
    Springfield, Illinois 62702, United States
    Recruiting
    • Namita Vinayek, MD · Contact
  • Mission Cancer and Blood
    Des Moines, Iowa 50309, United States
    Recruiting
    • Seema Harichand-Herdt, MD · Contact
  • Ochsner Medical Center (OMC)
    New Orleans, Louisiana 70121, United States
    Recruiting
    • Melanie Sheen, MD · Contact
  • Profound Research LLC at Michigan Hematology and Oncology Consultants
    Royal Oak, Michigan 48073, United States
    Recruiting
    • Savitha Balaraman, MD · Contact
  • St. Vincent Frontier Cancer Center (SVFCC) - Billings (Frontier Cancer Center and Blood Institute)
    Billings, Montana 59102-6746, United States
    Recruiting
    • Patrick Cobb, MD · Contact
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
    Recruiting
    • Jeffrey Neidhart, MD · Contact
  • New York Oncology Hematology - Amsterdam Cancer Center
    Amsterdam, New York 12010, United States
    Recruiting
    • Ami Negandhi, MD · Contact
  • Chelsea Medical Center at Mount Sinai
    New York, New York 10011, United States
    Recruiting
    • Paula Klein, MD · Contact
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
    Recruiting
    • Jinyu Lu, MD · Contact
  • Clinical Research Alliance
    Westbury, New York 11590, United States
    Recruiting
    • Jonathan Goldberg, MD · Contact
  • WakeMed Cancer Care - Waverly Hematology & Medical Oncology
    Cary, North Carolina 27518, United States
    Recruiting
    • Pallavi Kopparthy, MD · Contact
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
    Recruiting
    • Shimoli Barot, MD · Contact
  • The Mark H. Zangmeister Center-Mid Ohio Oncology/Hematology, Inc.
    Columbus, Ohio 43219, United States
    Recruiting
    • Jeanna Knoble, MD · Contact
  • St. Luke's University Health Network
    Bethlehem, Pennsylvania 18015, United States
    Recruiting
    • Maria Hafez, MD · Contact
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
    Recruiting
    • Cristina Truica, MD · Contact
  • Guthrie Medical Group
    Sayre, Pennsylvania 18840, United States
    Recruiting
    • Joyson Poulose, MD · Contact
  • Oncology Consultants PA
    Houston, Texas 77030, United States
    Recruiting
    • Ricardo Alvarez, MD · Contact
  • Cancer Care Northwest
    Spokane, Washington 99202, United States
    Recruiting
    • Saritha Thumma, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's planned 5 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2025
First posted
Dec 30, 2025
StartActual
Oct 20, 2026
Primary completionEst.
Mar 30, 2027
CompletionEst.
Jul 31, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 2 sites removed
Show 7 added (7 United States)
  • University of Illinois at Chicago · Chicago, United States
  • Mission Cancer and Blood · Des Moines, United States
  • WakeMed Cancer Care - Waverly Hematology & Medical Oncology · Cary, United States
  • Cancer Care Northwest · Spokane, United States
  • Regis Clinical Research · Miami, United States
  • Clinical Research Alliance · Westbury, United States
  • Penn State Milton S. Hershey Medical Center · Hershey, United States
Show 2 removed
  • NorthShore University HealthSystem - Evanston Hospital · Evanston, United States
  • Clinical Research Alliance Inc · Westbury, United States
across 2 updates, Oct 13, 2026 – Nov 12, 2026
Start date
Oct 30, 2026→Oct 20, 2026 (actual)
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    3 sites added, 1 site removed
    Show 3 added (3 United States)
    • Regis Clinical Research · Miami, United States
    • Clinical Research Alliance · Westbury, United States
    • Penn State Milton S. Hershey Medical Center · Hershey, United States
    Show 1 removed
    • Clinical Research Alliance Inc · Westbury, United States
    Start date Oct 30, 2026→Oct 20, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 13, 2026
    4 sites added, 1 site removed
    Show 4 added (4 United States)
    • University of Illinois at Chicago · Chicago, United States
    • Mission Cancer and Blood · Des Moines, United States
    • WakeMed Cancer Care - Waverly Hematology & Medical Oncology · Cary, United States
    • Cancer Care Northwest · Spokane, United States
    Show 1 removed
    • NorthShore University HealthSystem - Evanston Hospital · Evanston, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07310420
Lead sponsor
TerSera Therapeutics LLC
Responsible party
Sponsor
First posted
Dec 30, 2025
Start date
Oct 20, 2026
Primary completion
Mar 30, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Christine Fredericks
Contact
christine.fredericks@tersera.com
1-888-600-8116
Christine Fredericks
study director · TerSera Therapeutics LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goserelin

Start the discussion